Long-term tamoxifen citrate ue and potential ocular toxicity Original Reearch Article

Purpoe To etimate the prevalence of abnormalitie in viual function and ocular tructure aociated with the long-term ue of tamoxifen citrate. Method A ingle-maked, cro-ectional tudy involving multiple community and intitutional ophthalmologic department wa conducted with a volunteer ample of 303 women with breat cancer currently taking part in a randomized clinical trial to determine the efficacy of tamoxifen (20 mg/day) in preventing recurrence. Participant included women who had never been on drug (n = 85); women who had taken tamoxifen for an average of 4.8 year, then been off the drug for an average of 2.7 year (n = 140); and women who had been on tamoxifen continuouly for an average of 7.8 year (n = 78). Women were evaluated by quetionnaire, pychophyical teting, and clinical examination to determine any abnormalitie in viual function and the comparative prevalence of corneal, len, retinal, and optic nerve pathology. Reult There were no cae of viion-threatening ocular toxicity among the tamoxifen-treated participant. Compared with nontreated participant, the tamoxifen-treated women had no difference in the activitie of daily viion, viual acuity meaurement, or other tet of viual function except for color creening. Intraretinal crytal (odd ratio [OR] = 3.58, P =.178) and poterior ubcapular opacitie (OR = 4.03, P =.034) were more frequent in the tamoxifen-treated group. Concluion Women hould have a thorough baeline ophthalmic evaluation within the firt year of initiating tamoxifen therapy and receive appropriate follow-up evaluation.